DNA Damage Response from Molecular Mechanisms to Cancer Therapy
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: 20 September 2025 | Viewed by 1616
Special Issue Editors
Interests: DNA damage response; homologous recombination; DNA repair pathway choice; R-loop; post-translational modification; breast cancer; synthetic lethality
2. Department of Medical Biotechnology, University of Siena, 53100 Siena, Italy
Interests: cell cycle dependent kinase (CDK); retinoblastoma protein family; cancer therapy; mesothelioma; CDK9; Rb2
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The DNA damage response (DDR) could be defined as a double face of tumour: both the cause and treatment. Some DDR proteins are involved in the cancer-prone syndrome as in the ataxia telangiectasia (ATM) or Nijmegen Breakage syndrome (Nibrin), correlating them as tumour-developing factors. Conversely, the DNA repair defects are used as the “Achille’s heel” of cancer, favouring treatment with DNA damage agents through radiation therapy or cisplatin generating various kinds of DNA lesions (single or double strand breaks), although the side effects exerted on healthy tissue limits the use of this cancer therapy. In this scenario, the identification of novel therapeutic strategies based on the personal genetic makeup could be essential for improving the cancer treatments. To this aim, the dissection of novel proteins involved in the DDR plays an important role in cancer therapy. The discovery of highly selective actions of PARP inhibitors for BRCA1-/- breast cancer cells opened a “synthetic lethal era”. BRCA1 is one of the first players in the homologous recombination (HR), the error-free DNA repair mechanism based on the use of sister chromatids for genetic information stability. Moreover, the appearance of various resistance mechanisms to PARP inhibitors, such as functional BRCA1 and BRCA2 reactivation, the loss of 53BP1, or replication fork stability, suggest the necessary discovery of new players in order to bypass the tumour-resistance phenomena through the identification of alternative therapeutic targets.
This Special Issue will highlight novel discoveries in the context of the DNA damage response, from molecular mechanisms to clinical aspects, as potential novel strategies for cancer therapy.
Dr. Luigi Alfano
Prof. Dr. Antonio Giordano
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- DNA damage response
- synthetic lethality
- homologous recombination
- cancer therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
